- Home
- PHVS vs EEX Comparison
PHVS vs EEX Comparison
Compare PHVS & EEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHVS
- EEX
- Stock Information
- Founded
- PHVS 2015
- EEX 2013
- Country
- PHVS Switzerland
- EEX United States
- Employees
- PHVS N/A
- EEX N/A
- Industry
- PHVS Biotechnology: Pharmaceutical Preparations
- EEX Advertising
- Sector
- PHVS Health Care
- EEX Consumer Discretionary
- Exchange
- PHVS Nasdaq
- EEX Nasdaq
- Market Cap
- PHVS 909.5M
- EEX 749.0M
- IPO Year
- PHVS 2021
- EEX 2017
- Fundamental
- Price
- PHVS $16.49
- EEX $4.63
- Analyst Decision
- PHVS Strong Buy
- EEX Strong Buy
- Analyst Count
- PHVS 5
- EEX 2
- Target Price
- PHVS $39.20
- EEX $7.90
- AVG Volume (30 Days)
- PHVS 59.6K
- EEX 102.8K
- Earning Date
- PHVS 05-13-2025
- EEX 05-01-2025
- Dividend Yield
- PHVS N/A
- EEX 1.30%
- EPS Growth
- PHVS N/A
- EEX N/A
- EPS
- PHVS N/A
- EEX 0.02
- Revenue
- PHVS N/A
- EEX $413,100,000.00
- Revenue This Year
- PHVS N/A
- EEX $14.85
- Revenue Next Year
- PHVS N/A
- EEX $6.42
- P/E Ratio
- PHVS N/A
- EEX $186.11
- Revenue Growth
- PHVS N/A
- EEX 4.87
- 52 Week Low
- PHVS $11.51
- EEX $3.22
- 52 Week High
- PHVS $25.50
- EEX $6.74
- Technical
- Relative Strength Index (RSI)
- PHVS 51.83
- EEX 59.59
- Support Level
- PHVS $15.46
- EEX $4.40
- Resistance Level
- PHVS $16.99
- EEX $4.68
- Average True Range (ATR)
- PHVS 1.04
- EEX 0.12
- MACD
- PHVS -0.08
- EEX -0.03
- Stochastic Oscillator
- PHVS 71.48
- EEX 52.51
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
About EEX Emerald Holding Inc.
Emerald Holding Inc is an operator of B2B trade shows in the United States. The company is engaged in three complementary business lines; Connections division consists of a collection of B2B trade show franchises and other live events that provide exhibitors opportunities to engage with buyers and expand their brand's awareness in their industry, Content division consists of B2B print publications and digital media products that complement existing trade show properties, and the Commerce division which offers software-as-a-service technology that enables year-round B2B buying and selling through Elastic Suite and Bulletin platforms for use by its customers. Majority of the revenue for the company is generated from its Connections segment.